A pharmaceutical composition for treating diseases related to inflammation or injury such as ARDS, comprising: (a) an active material derived from human somatic cells, the active ingredient being an extracellular vesicle produced by human somatic cells; and (b) a pharmaceutically acceptable carrier. The somatic cells are selected from human tissue, bone marrow and/or blood-derived stem cells, etc. The dosage form of the pharmaceutical composition is selected from an atomized inhalation agent, eye drops and nasal drops. The pharmaceutical composition has storage stability and high dispersibility superior to those of a living cell formulation. A method for preparing an extracellular vesicle, comprising steps of culturing human somatic cells, removing cells from a culture system, mixing a culture solution with polyethylene glycol to form an extracellular vesicle modified by PEG, centrifuging, resuspending, etc. The formulation of the extracellular vesicle can be used for preparing a medicament for preventing and/or treating inflammations or injuries.

The present disclosure relates to an organ extracellular matrix-derived scaffold for culture and transplantation of an organoid and a method of preparing the same.

A process of using a fish plasma component in a nutrient medium for cell culture includes obtaining a fish that is a progeny of domesticated broodstock that are reared under consistent and reproducible conditions. Blood is obtained from the fish, and plasma is separated from the blood. One or more specific components of the plasma are then extracted, and cells are cultured in a nutrient medium using the one or more extracted plasma components, and none of any remainder of the plasma. The plasma and/or the plasma components is/are tested for presence and/or level of endotoxin. Extracting the one or more specific components of the plasma, and/or culturing the cells is only performed if the testing indicates an endotoxin level below a predetermined threshold. The cells cultured using the extracted one or more plasma components are other than fish cells.

Provided are a biomarker identifying method including (1) to (4) and an application thereof. (1) An evaluation value for each of a plurality of biomarkers is derived based on annotation information imparted to each of biomarkers, and a measurement target biomarker is selected based on the evaluation value. (2) The evaluation data of the measurement target biomarker is acquired from the cell A and/or the culture system, before the start of culture of the cell A and/or during the culture. (3) The evaluation data of the discrimination marker of the B cell is acquired from the cell A and/or the culture system, at the final stage of the culture of the cell A and/or after the end of the culture. (4) At least one biomarker indicating characteristics of the cell A is identified from among the measurement target biomarkers, based on the data obtained from (2) and (3).

The present invention provides methods of inducing proliferation of and/or differentiating cells comprising contacting cells with compounds within the methods of the invention. The present invention further provides cells obtainable by the methods of the invention.

Chimeric transmembrane immunoreceptors (CAR) targeted to PSCA are described.

The present invention provides a primary cell culture which combines a cell culture medium and cells derived from a hypertrophied androgenic gland (AG) of a decapod crustacean. The invention also provides methods for obtaining an all-female progeny by initially injecting/transplanting the primary cell culture to a genetic-female to obtain a male-Neo-male.

The present invention provides inhibitors of fucosylation during protein expression from mammalian cells. The inhibitors are derived from rhamnose and act by inhibition of GDP-mannose 4,6-dehydratase (GMD). The invention further provides methods of making proteins with reduced level of fucosylation, such as antibodies and antibodies made by the methods of the present invention. Such hypofucosylated or nonfucosylated antibodies may find use, for example, in treatment of human disease in which is it therapeutically eneficial to direct antibody dependent cellular cytotoxicity (ADCC) mediated killing of cells expressing the antibody target on their surface, for example in depletion of Tregs in cancer patients using a hypofucosylated or nonfucosylated anti-CTLA-4 antibody.

The current disclosure provides methods and compositions useful in preparing transformed and immortalized zebra and quagga mussel cells that function as disseminated neoplastic (DN) cells, as well as the cells produced thereby. In particular, these cells are immortalized through modifying expression of the TERT nucleic acid and/or protein. Also provided are methods for using such mussel DNCs in cell culture, in vitro, and within live mussels in the lab or in the wild, to control mussel populations such as invasive zebra mussel or quagga mussel populations.

Disclosed herein is a method for manufacturing a population of human insulin producing cells from non-pancreatic β-cells, wherein the resulting insulin producing cells have increased insulin content, or increased glucose regulated secretion of insulin, or a combination of both.